Document Detail

Topical ranibizumab as a treatment of corneal neovascularization.
MedLine Citation:
PMID:  23407316     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).
METHODS: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.
RESULTS: Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.
CONCLUSIONS: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
Giulio Ferrari; Mohammad H Dastjerdi; Andre Okanobo; Sheng-Fu Cheng; Francisco Amparo; Nambi Nallasamy; Reza Dana
Related Documents :
24133026 - Recipient corneal thickness and visual outcome after descemet's stripping automated end...
1286236 - Ocular vitamin therapy. a review and assessment.
16126646 - Sleep and cognition in people with alzheimer's disease.
9591806 - Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-as...
12218706 - On-line versus off-line vestibular-evoked control of goal-directed arm movements.
22949916 - An unexpected delayed complication of cataract surgery: retinal detachment secondary to...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cornea     Volume:  32     ISSN:  1536-4798     ISO Abbreviation:  Cornea     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-10     Completed Date:  2014-01-08     Revised Date:  2014-07-02    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  992-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Blood Vessels / drug effects,  pathology
Cornea / blood supply
Corneal Neovascularization / drug therapy*,  physiopathology
Intraocular Pressure / physiology
Middle Aged
Ophthalmic Solutions
Prospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Grant Support
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Ophthalmic Solutions; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Azithromycin treatment increases survival of high-risk corneal allotransplants.
Next Document:  Handheld Slit Beam Techniques to Facilitate DMEK and DALK.